EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Terlipressin Administration Strategies in Hepatorenal Syndrome–Acute Kidney Injury: A Narrative Review of Continuous Infusion and Intermittent Bolus Approaches

Tien Q Pham iD, Stephanie N Bass iD, Jason R Yerke iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70084 ↗

At a glance

Übersichtsarbeit in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Written by Tien Q Pham and 2 co-authors. Institution: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: Terlipressin, Hepatorenal Syndrome, Vasoconstrictor Agents, Acute Kidney Injury. 31 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of cirrhosis, marked by profound splanchnic vasodilation leading to renal hypoperfusion. Guidelines throughout the years have refined the definitions, classifications, and diagnostic criteria of HRS‐AKI to promote earlier recognition and intervention. Vasoconstrictor therapy remains the cornerstone of the management of HRS‐AKI. Among the available agents, terlipressin is the most well‐studied and has been endorsed by multiple international guidelines as first‐line therapy for HRS‐AKI. Although approved by the United States Food and Drug Administration for use in HRS‐AKI with an intermittent intravenous bolus dosing strategy, recent consensus guidance recommends continuous infusion as the preferred route of administration. This narrative review summarizes current evidence from clinical trials and comparative studies evaluating terlipressin continuous infusion versus intermittent bolus dosing strategies, with a focus on efficacy, safety, and operational considerations. Clinical trials comparing the two strategies have shown that the continuous infusion strategy provides comparable, and possibly superior, efficacy in HRS reversal compared to intermittent bolus dosing, while also demonstrating a lower incidence of adverse effects. Operational feasibility is supported by physical and chemical stability in various diluents over 24‐h infusion periods; however, implementation challenges remain, including limited line compatibility data and line access issues in patients with cirrhosis. In conclusion, the terlipressin continuous infusion strategy appears to be an efficacious, safe, and operationally plausible alternative to intermittent bolus dosing and may be considered for routine use in clinical practice.

Subjects

MeSH terms (MEDLINE)

TerlipressinHepatorenal SyndromeVasoconstrictor AgentsAcute Kidney InjuryHumansInfusions, Intravenous

Author keywords

acute kidney injurycontinuous intravenous infusionhepatorenal syndromeliver cirrhosisterlipressinvasoconstrictor agents

Substances

TerlipressinVasoconstrictor Agents

Authors and institutions

  • Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID profiles: Tien Q Pham, Stephanie N Bass, Jason R Yerke

Cite

APA

Pham, T. Q., Bass, S. N., & Yerke, J. R. (2025). Terlipressin Administration Strategies in Hepatorenal Syndrome–Acute Kidney Injury: A Narrative Review of Continuous Infusion and Intermittent Bolus Approaches. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70084

Vancouver

Pham TQ, Bass SN, Yerke JR. Terlipressin Administration Strategies in Hepatorenal Syndrome–Acute Kidney Injury: A Narrative Review of Continuous Infusion and Intermittent Bolus Approaches. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70084

BibTeX
@article{Pham2025,
  author = {Pham, Tien Q and Bass, Stephanie N and Yerke, Jason R},
  title = {Terlipressin Administration Strategies in Hepatorenal Syndrome–Acute Kidney Injury: A Narrative Review of Continuous Infusion and Intermittent Bolus Approaches},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70084}
}
Start for free →